Coronary Heart Disease in Patients With Diabetes Part II: Recent Advances in Coronary Revascularization by Berry, Colin et al.
P
i
r
e
p
a
(
i
o
t
n
c
b
a
h
r
F
M
I
B
a
Journal of the American College of Cardiology Vol. 49, No. 6, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
PCoronary Heart Disease in Patients With Diabetes
Part II: Recent Advances in Coronary Revascularization
Colin Berry, MD, PHD, Jean-Claude Tardif, MD, FACC, Martial G. Bourassa, MD, FACC
Montreal, Quebec, Canada
Although diabetic patients represent approximately one-quarter of all those undergoing revascularization,
their outcomes after revascularization are usually worse compared with non-diabetic patients. We examined
the recent advances in percutaneous and surgical revascularization that are relevant to the treatment of
diabetic patients. A systematic review of publications in the past 5 years (2000 to 2005) relating to coro-
nary revascularization in diabetes was undertaken. Early and mid-term follow-up of diabetic patients after
revascularization indicates that the incidence of myocardial infarction and repeat revascularization are re-
duced in surgically treated patients compared with those treated by balloon angioplasty alone. Percutane-
ous coronary intervention (PCI) with bare metal stents has reduced the surgical advantage (for reinterven-
tion) in the early–mid-term; however, repeat revascularization in diabetic patients continues to be
substantially higher after PCI. Advances in PCI include the use of drug-eluting stents and adjunctive drug
therapies, such as abciximab. Glycemic control is an important determinant of outcome after revasculariza-
tion in diabetic patients, and the impact of tight glycemic control after PCI is currently being investigated in
the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 in Diabetes). Improvements in PCI and
coronary artery bypass graft surgery are leading to better results in diabetic patients, and clinical trials are
presently comparing contemporary PCI with surgery. (J Am Coll Cardiol 2007;49:643–56) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.045C
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satients with diabetes mellitus (DM) account for approx-
mately one-quarter of all patients who undergo coronary
evascularization procedures each year, and they experi-
nce worse outcomes compared with non-diabetic
atients.
The clinical trials of percutaneous transluminal coronary
ngioplasty (PTCA) versus coronary artery bypass grafting
CABG) that included diabetic patients have been reviewed
n this journal by Hammoud et al. (1). Since the publication
f that article and other more recent reviews (2,3), long-
erm follow-up data from these trials and from a number of
ew trials have become available. Although surgical revas-
ularization remains the recommended strategy for dia-
etic multivessel coronary heart disease (CHD), recent
dvances in percutaneous coronary intervention (PCI)
ave resulted in a changing paradigm for coronary artery
evascularization in DM.
rom the Department of Medicine, Montreal Heart Institute and Université de
ontréal, Montreal, Quebec, Canada. Dr. Tardif is the Pfizer and Canadian
nstitutes of Health Research Chair in Atherosclerosis. Dr. Berry is supported by a
ritish Heart Foundation International Fellowship.a
Manuscript received July 11, 2006; revised manuscript received September 7, 2006,
ccepted September 11, 2006.ABG Versus PTCA
ecent Findings From Previous
linical Trials With Long-Term Follow-Up
he EAST (Emory Angioplasty versus Surgery Trial)
tudy. The EAST study was a single-center randomized
omparison of a strategy of initial PTCA (n 198; 49
24.7%] DM) or CABG (n  194; 41 [21.2%] DM) for
atients with multivessel CHD (4) (Table 1).
The 8-year survival was 79.3% in the PTCA group and
2.7% in the surgical group (p  0.40); however, survival
ended to be greater in diabetic patients who underwent
ABG (75.5%) compared with those who underwent PTCA
60.1%; p  0.23). In the angioplasty group, diabetic subjects
ad a reduced survival rate compared with non-diabetic sub-
ects (60.1% vs. 82.6%; p  0.02). By 8 years, a repeat revascu-
arization occurred in 26.5% of the CABG-treated patients and in
5.3% of the PTCA-treated patients (p  0.001).
he BARI (Bypass Angioplasty Revascularization Inves-
igation) Study. The BARI study was a National Heart,
ung, and Blood Institute-sponsored trial designed to compare
ong-term survival in patients with multivessel disease and severe
ngina or ischemia randomized to PTCA or CABG (1,5,6).
ONG-TERM SURVIVAL. The BARI 10-year follow-up re-
ults should be available soon; the current intention-to-treat
nalysis, however, is limited to 7 years (1,5–7) (Table 1).
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Diabetes and Coronary Heart Disease: Part II February 13, 2007:643–56The survival advantage in the
CABG group was largely confined
to patients who had received an
internal mammary artery (IMA)
graft to the left anterior descend-
ing artery (LAD) (83.2%, n 
140) compared with those who
had received only saphenous vein
grafts (SVGs) (54.5%, n  33)
(7). The difference between the 2
groups was explained by the 353
patients with treated DM for
whom estimates of 7-year sur-
vival were 76.4% and 55.7% in
those treated by CABG and
PTCA, respectively (p  0.001).
At 5 years, the BARI study
showed 15 excess deaths for ev-
ery 100 diabetic patients revascu-
larized by PTCA compared with
CABG, and at 7 years this dif-
ference increased to 20. The
predictors of mortality in BARI
included insulin-treated DM,
heart failure and renal failure,
black race, and older age (8). The
only significant interaction term
for survival was insulin-treated
DM (p  0.042).
In the BARI study, CABG
was associated with better sur-
vival in the randomized diabetic
patients (n  353) (9); however,
in the registry patients (n 
339), there was no difference
(10). The different outcomes be-
tween the BARI study and reg-
istry might be explained by dif-
erences in the characteristics of registry patients who had a
elected revascularization strategy. For example, CABG
egistry patients had more extensive coronary artery disease
nd a lower left ventricular ejection fraction than PTCA
egistry patients, suggesting the latter group were lower risk.
EPEAT REVASCULARIZATION IN BARI. Repeat revascular-
zation in CABG-treated patients was similar in diabetic
atients and in non-diabetic patients (11.1% vs. 13.5%; p 
.45) (7). In PTCA-treated patients, repeat revasculariza-
ions were much more common in diabetic patients than in
on-diabetic patients (69.9% vs. 57.8%; p  0.0078).
ECHANISMS TO EXPLAIN THE SURVIVAL BENEFITS OF CABG
ERSUS PTCA IN DIABETIC PATIENTS IN THE BARI
TUDY. The BARI investigators undertook a follow-up
ngiographic core laboratory analysis of all patients under-
oing protocol-driven coronary angiography at years 1 and 5
Abbreviations
and Acronyms
BMI  body mass index
BMS  bare-metal stent
CABG  coronary artery
bypass grafting
CHD  coronary heart
disease
CI  confidence interval
CKMB  creatine kinase
isoenzyme MB
DES  drug-eluting stent
DM  diabetes mellitus
IMA  internal mammary
artery
LAD  left anterior
descending
LMS  left main stem
MACCE  major adverse
cardiac and
cerebrovascular events
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
PTCA  percutaneous
transluminal coronary
angioplasty
RR  relative risk
SES  sirolimus-eluting
stent
SVG  saphenous vein graft
TLR  target lesion
revascularization
TVR  target vessel
revascularization11). Patients who underwent repeat angiography because of Ra T
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February 13, 2007:643–56 Diabetes and Coronary Heart Disease: Part IIecurrent ischemia were also included in this analysis. The
ercentage of myocardium jeopardized represented the frac-
ion of all terminal arteries with evidence of stenoses 50%
f the reference diameter. On multivariate analyses, DM
onferred a 2-fold risk of an increased percentage of
eopardized myocardium during follow-up.
Diabetic patients had a greater mortality risk with acute
-wave MI compared with non-diabetic patients, and
etre et al. (12) hypothesized that previous CABG might
mpact upon this risk. In this analysis, randomized and
egistry patients who underwent either CABG or PTCA
ere studied together (n 1,512 [290 with DM]). Diabetic
atients were more likely to be female and black and more
ikely to have a history of heart failure, hypertension, renal
ysfunction, and peripheral vascular disease.
Coronary artery bypass grafting conferred a substantial
rotective effect for mortality in diabetic subjects with a
-wave MI (adjusted relative risk [RR] of death 0.09; p 
001) (12). The protective effect of CABG was 7 times
reater in diabetic patients who experienced a Q-wave MI
ompared with those who did not. In these patients, CABG
educed the risk of death but to a much lesser extent.
verall, the protective effect of CABG for a patient with an
I explained only about 50% of the overall reduction in
ortality attributable to the procedure. The remaining
enefit of CABG among the patients with DM was
emonstrated by a further reduction in mortality during
ollow-up, perhaps a result of the reduction in the degree of
hronic ischemia. This can probably be explained by the
ore extensive revascularization provided by CABG and
he protection provided by these conduits with recurrent
oronary events.
Incomplete revascularization is particularly important in
M, owing to the increased risk of restenosis and disease
rogression in PTCA-treated diabetic patients. In BARI,
hereas the amount of jeopardized myocardium was greater
n PTCA-treated (25%) compared with CABG-treated
atients (20%; p  0.01), late angina was predicted by
yocardial jeopardy (odds ratio [OR]/10% increase 1.22,
5% confidence interval [CI] 1.09 to 1.36), severity of
ngina at baseline (OR 2.2, 95% CI 1.17 to 4.14), and a
istory of cigarette smoking (OR 1.91, 95% CI 1.09 to 3.35)
ut not treatment assignment. In other words, native CHD
rogression and CHD risk factors were more important
han failed revascularization (13).
esults of registries (PTCA vs. surgery) with long-term
ollow-up. Although the BARI and CABRI (Coronary
ngioplasty versus Bypass Revascularization Investigation)
14) studies demonstrated a lower mortality in CABG-
reated diabetic patients and the EAST study also showed a
rend in favor of bypass surgery (Table 1), this was not the
ase in a large European registry (15) (Fig. 1). Impaired
ong-term outcomes in CABG patients might be explained
y late onset graft failure and heart failure (16). However,
ur interpretation of these registry reports (15,16) should olso account for the likelihood of selection bias, which
sually influences the management of registry patients.
elevance of PTCA versus surgery trials for contempo-
ary practice. The findings from trials of PTCA versus
urgery have provided major advances in our understanding
f revascularization in diabetes (4,7,14). However, contem-
orary revascularization practices have made substantial
rogress, and this is particularly the case in PCI. Therefore,
rom the perspective of clinical decision making, the results
f these trials are of historical interest only.
ABG Versus PCI With Bare-Metal Stents
he ARTS (Arterial Revascularization Therapy Study) trial
ompared outcomes from bypass surgery versus coronary
tenting in patients with multivessel disease. In the ARTS
rial (17) (Table 2), the reduced event-free survival at 1 year
n diabetic patients treated with stenting as compared with
iabetic patients treated with CABG (63.4% vs. 84.4%, p
.001) and nondiabetic patients treated with stents (76.2%,
 0.04) was due to a higher incidence of repeat revascu-
arization (typically CABG). This difference was largely due
o a lower rate of complete revascularization in patients who
nderwent PCI (70.5%), compared with those who had
ABG (84.1%; p  0.001). Conversely, diabetic and
ondiabetic patients experienced similar 1-year event-free
urvival rates when treated with CABG (84.4% and 88.4%).
he strategy of stenting was less costly than that of CABG
egardless of diabetic status (17).
The 5-year mortality rate of diabetic patients in the stent
roup was 13.4% compared with 8.3% in the surgical group
RR 1.61, 95% CI 0.71 to 3.63). Within the stent group,
he mortality of diabetic patients remained higher than that
Figure 1 Cumulative Survival Rates After PTCA or
CABG in Diabetic and Nondiabetic Patients
Cumulative un-adjusted survival in 1,041 patients (8% with treated diabetes
mellitus [DM]) who underwent coronary artery bypass grafting (CABG) between
1970 and 1985 and 702 (11% with treated DM) who underwent first percuta-
neous transluminal coronary angioplasty (PTCA) between 1980 and 1985. Anal-
yses of patients after 10 to 20 years follow-up revealed survival rates in
surgically treated patients to be lower than PTCA-treated patients. Reproduced
from van Domburg et al. (15) with permission.f nondiabetic patients (13.4% vs. 6.8%; p  0.03), whereas
Randomized Clinical Trials That Have Compared PCI With Stents Versus Bypass Surgery in Patients With Multivessel CAD Deemed Suitable for Either Approach
Table 2 Randomized Clinical Trials That Have Compared PCI With Stents Versus Bypass Surgery in Patients With Multivessel CAD Deemed Suitable for Either Approach
Trial (Ref.)
Randomization
Period Primary End Point Eligible Number of Patients Randomized Follow-Up Primary End Point Primary End Point in DM
ARTS (17) April 1997–
June 1998
Multivessel CAD Freedom for 12 months
after randomization,
from MACCE
1,205
PCI  600;
DM  112 (19%)
CABG  605;
DM  96 (16%)
1 yr PCI: 73.8%;
CABG: 87.8%
p  0.001
PCI: 63.4%;
CABG: 84.4%
p  0.001
SOS (19) 1996–1999 Symptomatic
multivessel
disease
Repeat revascularization 988
PCI  488 (DM  68)
CABG  500 (DM  74)
Median 2 yrs PCI group: 101 (21%)
CABG group: 30 (6%)
N/A
ERACI II (20,21) October 1996–
September
1998
Multivessel CAD MACE 450
(PCI  225; CABG  225)
Diabetes 17.3% both groups
30 days,
1, 3, and
5 yrs
30-day PCI: 3.6%
CABG: 12.3%
p  0.002
5-yr PCI: 34.7%
CABG: 23.6%
p  0.013
Similar 30 days (PCI vs. CABG) outcomes
in DM
5-yr mortality:
PCI DM vs. PCI noDM: 10% vs. 6.4%;
p  0.663
CABG DM vs. CABG noDM: 10.2% vs.
11.8%; p  0.637
AWESOME (22) 1995–2000 Medically refractory
unstable angina
and at least 1
high-risk feature
for CABG
LMS an exclusion
criterion
Survival at 3 and 5 yrs 454 (58%) randomized; 1,977 (1,650 [83%]
physician-directed; 327 [17%] patient
choice) entered into registry.
DM  32% (n  144) in randomized
patients, 27% (n  89) in patient- and
32% (n  525) in physician-directed
registries, respectively. 93 physician-
directed and 4 patient-directed diabetic
patients received medical care.
36 months,
5 yrs
Survival PCI (80%)
and CABG (79%)
groups
NS
Similar 3-yr survival rates DM: n  67 vs.
n  81, 80% vs. 73%, respectively;
DM: n  155 vs. n  151, 79% vs.
80%, respectively. 5 yr freedom from
UA or repeat PCI/CABG in DM: CABG
group 43% vs. PCI group 23%
No other between-group differences at
5 yrs
MACE  major adverse cardiac events (death, Q-wave MI, or stroke, and need for emergency or elective repeat revascularization); MACCE  major adverse cardiac and cerebrovascular events; N/A  not applicable; NS  not significant; other abbreviations as in Table 1.
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February 13, 2007:643–56 Diabetes and Coronary Heart Disease: Part IIhe cardiac death rates were similar in diabetic (50%) and
ondiabetic patients (38%). The mortality rates of diabetic
nd nondiabetic patients in the surgical group were similar
8.3% vs. 7.5%; p  0.8). In the stent group, repeat
evascularizations were much more frequent in diabetic
42.9%) compared with nondiabetic patients (27.5%; p 
.002), and this difference was reflected by the 5-year major
dverse cardiac and cerebrovascular event (MACCE) rates
f diabetic and nondiabetic patients (54.5% vs. 38.7%; p 
.003) (18).
At least 3 additional trials have compared PCI with
are-metal stents (BMS) versus bypass surgery in patients
ith multivessel CHD (19–22) (Table 2). The SOS (Stent
r Surgery) trial showed less repeat revascularization with
ABG than with PCI overall at 2 years, but the diabetic
ubgroup was not analyzed separately (19). The 2 other
rials showed mixed results (20–22), as shown in Table 2.
egistry results: impact of PCI with stents in diabetes.
rinivas et al. (23) examined the impact of contemporary
CI in patients treated in the late 1990s compared with
atients treated with PTCA without stents. The 904 BARI
atients who had been randomized to PTCA were com-
ared with 857 patients (23% with treated DM; 14%
on–insulin-treated, 8% insulin-treated) with BARI ran-
omization characteristics who were enrolled in the U.S.
ational Heart, Lung and Blood Institute (NHLBI) Dy-
amic Registry in 2 waves in 1997 to 1998 and in 1999
23,24). A lower proportion of diabetic patients were
andomized to BARI-PTCA (10%), compared with the
ARI-Eligible Dynamic Registry (23%; p  0.047). Gly-
oprotein IIb/IIIa inhibitor use in the Dynamic registry
opulation was 24%. Bare-metal stents were used in 74% of
he contemporary group compared with 1% in the BARI
roup. Compared with PTCA-treated patients, contempo-
ary PCI-treated patients had a lower risk of subsequent
ABG (hazard ratio [HR] 0.35, 95% CI 0.26 to 0.48, p 
.001), PCI (HR 0.56, 95% CI 0.43 to 0.71, p  0.001), or
ABG/PCI (HR 0.41, 95% CI 0.33 to 0.51, p  0.001) at
year.
ABG Versus PCI With Drug-Eluting Stents
rug-eluting stents represent a major advance for the
revention of restenosis and repeat revascularization after
CI in diabetic patients (25–28) (Table 3). However, as in
he SIRIUS (SIRolImUS-coated Bx Velocity stent) study
26), DM was an independent predictor of target lesion
evascularization (TLR) (OR 1.54, 95% CI 1.04 to 2.27) in
he paclitaxel-eluting TAXUS IV study (27) (Table 3).
Because diabetic patients did not represent a pre-specified
ubgroup in the SIRIUS (26) or TAXUS IV (27) studies,
he role of DES for diabetic patients has been questioned
29). A thick strut BMS, used in the control group of these
rials, is associated with a higher rate of restenosis compared
ith thin strut stents, and the relatively high BMS TLRate observed in the DES trials probably enhanced the bpparent anti-restenotic effects of the new DES. Further-
ore, only a proportion of diabetic patients underwent
ngiographic follow-up in the TAXUS IV study (27).
epeat angiography can positively influence TLR, which
ight be higher than in studies with clinical follow-up only.
his potential for bias might be particularly relevant for
iabetic patients in whom restenosis might not be apparent,
wing to silent ischemia (29). The DIABETES (Diabetes
nd Sirolimus-Eluting Stent) trial specifically assessed the
ffects of a sirolimus-eluting stent (SES) in DM (28).
otably, late loss at stent edges was similar in the SES and
MS groups. This might be explained by relative drug
paring at the edge of the stent, injury at the peri-stent zone,
nd geographic miss.
In the SIRTAX (SIRolimus- versus pacliTAXel-eluting
tents) trial (30) (Table 3), the HR for MACCE was less in
ES-treated patients compared with in paclitaxel-eluting
tents (PES)-treated patients and this difference was more
ronounced in DM. In the ISAR (In-Stent Angiographic
estenosis)-DIABETES trial (31) (Table 3), PCI with
ES resulted in less in-segment restenosis in insulin-treated
p  0.02) and non–insulin-treated (p  0.03) diabetic
atients. Although this trial was not powered to compare
linical events, its results suggest that SES might be
referred to PES for PCI in DM.
The SYNTAX (SYNergy between percutaneous coro-
ary intervention with TAXus and cardiac surgery) (32) and
OMBAT (COMparison of Bypass surgery and Angio-
lasTy using sirolimus stents in patients with unprotected
eft main coronary artery disease) (33) are ongoing trials of
CI with DES versus surgery that will provide more
nformation on revascularization in DM.
ecommendations of
ontemporary PCI Guidelines
ontemporary PCI guidelines place emphasis on the long-
erm survival benefit conferred by CABG for treatment of
M with multivessel disease. Clinician’s judgment on the
evascularization strategy remains an important factor. Al-
hough PCI with BMS have narrowed the gap with surgery,
he effectiveness of PCI in CABG-eligible diabetic patients
ith stable or unstable multivessel disease (including prox-
mal LAD disease) must be established by the on-going
andomized trials (33–36) (Table 3) (American College of
ardiology/American Heart Association [ACC/AHA]
uideline recommendation Class IIB; Level of Evidence: B)
37).
Invasive management in diabetic patients with unstable
HD is indicated on clinical need and should be guided by
vidence of ischemia and by risk stratification (37). A recent
eta-analysis that included 1,465 (18.9%) diabetic patients
as confirmed that higher-risk unstable angina/non–ST-
egment elevation MI patients (e.g., biomarker positive)
enefit from a routine invasive strategy (38).
Published and Ongoing Randomized Trials of PCI With Drug-Eluting Stents Versus Bare Metal Stents
Table 3 Published and Ongoing Randomized Trials of PCI With Drug-Eluting Stents Versus Bare Metal Stents
Trial (Ref.) Status Inclusion and Exclusion Criteria Primary End Point Intervention
Number of Patients
Randomized Follow-Up Primary End Point
Primary End Point
in DM
BARI 2D (34) Ongoing Type 2 DM. 1 vessel amenable to
revascularization (50%
stenosis)
Objective ischemia or typical
angina with 70% stenosis in
1 artery
Suitability for revascularization by
at least 1 available method
(does not require complete
revascularization)
5-yr mortality 1) Initial elective coronary
revascularization combined with
aggressive medical therapy,
compared with an initial strategy of
aggressive medical therapy alone
2) Efficacy of a strategy of providing
more insulin (endogenous or
exogenous) vs. a strategy of
increasing sensitivity to insulin
(reducing insulin resistance) in the
management of hyperglycemia, with
a target HbA1c level of 7.0% for
each strategy
2,368 5 yrs — —
CARDIA (35) Ongoing Diabetes. Multivessel CAD (2
stenotic coronary or 1 in which
PCI suitability is unclear: e.g.,
bifurcation lesion involving
proximal LAD)
Consensus between a cardiologist
and surgeon that adequate
revascularization can be
achieved
Death, non-fatal
MI, or stroke
within 1 yr
Optimal PCI includes the use of aspirin,
clopidogrel, abciximab, and
sirolimus-eluting stents in all
patients
Modern CABG is defined as 1 arterial
conduit with a LIMA graft for the
anterior native vessels and off-pump
bypass at the surgical team’s
discretion
600 projected 1–5 yrs — —
FREEDOM (36) Ongoing Diabetes. Multivessel CAD (2
lesions in 2 major arteries),
amenable to either PCI with DES
or surgical revascularization.
All-cause
mortality, MI,
and stroke
Compares multivessel stenting using
sirolimus-eluting stents with CABG
Superiority trial
2,400 projected 5 yrs — —
COMBAT (33) Ongoing Inclusion: LMCA stenosis 50%
(visual estimate); angina or
documented ischemia
amenable to both PCI or CABG;
lesions outside LMCA amenable
to both PCI or CABG
Exclusion: previous PCI (12
months); previous LMCA PCI;
previous CABG; LVEF 20%;
NYHA heart failure class III or IV
All-cause
mortality, MI,
and stroke at
2 yrs
Randomization stratified by diabetes 1,730 projected
(1:1 SES vs.
CABG)
5 yrs — —
SYNTAX (32) Ongoing Inclusion: stable or unstable angina
or atypical presentation with
ischemia; de novo lesion; 1
stenosis in all 3 major epicardial
arteries supplying viable
myocardium or significant LMCA
stenosis or equivalent; reference
diameter 1.5 mm
Exclusion: previous PCI or CABG;
1- or 2-vessel CAD without LMCA
disease
MACCE to 1 year PCI with PES vs. CABG
Randomization stratified by treated-DM.
DM is a predefined subgroup (including
by type, treatment, and hemoglobin
A1c)
1,500 (750 per
group)
5 yrs — —
Continued on next page
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Continued
Table 3 Continued
Trial Status Inclusion and Exclusion Criteria Primary End Point Intervention
Number of Patients
Randomized Follow-Up Primary End Point
Primary End Point
in DM
SIRIUS (25) Published Inclusion: stable or unstable angina
and evidence of myocardial
ischemia correlated with a
de novo native coronary
stenoses 50%–99% diameter,
15–30 mm in length, and
2.5–3 mm in diameter
Target vessel
failure
(composite of
cardiac death,
MI, and TVR)
within 270 days
of the index PCI
PCI with Cypher Stent (Cordis) vs. PCI
with BMS (BxVelocity, Cordis)
SES (131/533
[25%]:DM)
BMS (148/525
[28%]:DM)
270 days All patients:
SES: 8.6%
BMS: 21.0%
p  0.001
SES: 12.2%
BMS: 27.0%
p  0.003
TAXUS IV (27) Published Inclusion: single, de novo lesion
estimated visually to be
between 10 to 28 mm in length,
with a reference vessel diameter
2.5–3.75 mm
TVR at 9 months PCI with PES (Taxus, Boston Scientific)
vs. PCI with BMS (Express, Boston
Scientific)
PES: DM 23.4%
(of total  662)
(7.7% insulin
requiring)
BMS: 25.0%
(of total  652)
(8.3% insulin-
requiring)
1 yr PES: 4.7%
BMS: 12%
RR 0.39
p  0.001
Paclitaxel: 11.3%
BMS: 24%
RR 0.53
p  0.004
DIABETES (28) Published Insulin or non-insulin requiring
treated DM
Native vessel de novo lesion with a
reference vessel diameter
4.0 mm by angiography
Exclusion: LMS, ejection fraction
25%
In-segment late
lumen loss at
270 days
PCI with SES (Cypher, Cordis) vs. PCI
with BMS (standard stent)
SES (80;
lesions 111)
BMS (80;
lesions 110)
270 days — SES: 0.06 (0.4)
BMS: 0.47 (0.5)
p  0.001
SIRTAX (30) Published Stable angina or an acute coronary
syndrome
Native vessel de novo lesion
(50%) with a reference
diameter of 2.25–4 mm
MACE by 9 months PCI with SES (Cypher, Cordis) vs. PCI
with PES (Taxus, Boston Scientific)
SES: 503
(DM: 108 [21.5%])
PES: 509
(DM: 93 [18.3%])
9 months SES: 31 (6.2%)
PES: 55 (10.8%)
p  0.009
SES vs. PES
HR (95% CI): 0.31
(0.12–0.78)
DM vs. no DM
p  0.13
ISAR-DIABETES (31) Published DM with angina or a positive stress
test and a native vessel culprit
lesion
Exclusion: ST-segment elevation MI,
LMS disease, restenosis
NB. Pre-treatment with 600 mg of
clopidogrel 2 h pre-procedure
Difference in
mean n-
segment late
lumen loss at
9 months
Trial designed to
test non-
inferiority of
PES vs. SES
PCI with SES (Cypher, Cordis) vs. PCI
with PES (Taxus, Boston Scientific)
SES: 125
PES: 125
196 days
(median
angiographic
follow-up)
— 0.24 (0.09–0.39) mm
SES superior to PES
(p  0.002)
BMS  bare-metal stent; DES  drug-eluting stent; LAD  left anterior descending; LIMA  left internal mammary artery; LMCA  left main coronary artery; MACE  major adverse cardiac events; PCI  percutaneous coronary intervention; RR  relative risk; PES 
paclitaxel-eluting stent; SES  sirolimus-eluting stent; TLR  target lesion revascularization; TVR  target vessel revascularization; other abbreviations as in Table 1.
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mpaired Revascularization Outcomes in DM
dverse Outcomes After Surgery
ostoperative complications. Compared with nondiabetic
atients, early and long-term morbidity and mortality are
igher in diabetic patients after CABG (39), with more
ostoperative complications, including wound infection
40).
In the ARTS trial, creatine kinase isoenzyme MB
CKMB) measurements were performed at 6, 12, and 18 h
fter CABG (41). A CKMB rise 1 to 3 times the upper
imit of normal (ULN), 3 to 5  ULN, and 5 ULN
ccurred in 42.9%, 7.5%, and 11.5% of patients (61.9%
verall). Diabetes was an independent predictor of a reduced
ikelihood of CKMB elevation after CABG (OR 0.53, p 
.01) (41), and the authors argued this might be due to
educed CK activity in diabetes. In a recent trial of the
nti-inflammatory C5 complement inhibitor during
ABG, 55.6% of the 785 patients who had full CKMB
ssessment had a postoperative CKMB concentration 5
LN (25 ng/ml) (42,43). Compared with placebo, pexeli-
umab reduced the incidence of MI at 30 days (RR
eduction 18%; p  0.04) but not the combined end point
f 30-day death or MI (43). Myocardial infarction through
ay 4 predicted 30-day mortality.
omplications in the longer term. Angiographic analyses
f diabetic patients in the BARI study demonstrated that
espite smaller and more diseased native vessel targets,
rterial and vein graft patency rates were similar after an
verage of 4 years’ follow-up (44). Therefore, the worse
urvival of diabetic CABG patients compared with nondi-
betic surgical patients in the BARI study (7) might be
xplained by non-cardiac complications (44).
Cognitive decline is common after CABG (45); however,
hether this is a surgical complication or the natural history
f cognitive function in CHD is controversial (46). Decline
n cognitive function after CABG is not associated with
M (45). Stroke occurs more commonly in diabetic pa-
ients after CABG (17), and in the longer term, quality of
ife after CABG might be particularly reduced in DM (47).
ncreasing burden of vein graft disease. A recent CABG
rial reported a similarly high 12-month incidence of death
r SVG stenosis 75% in diabetic (48.3%) and nondiabetic
44.2%) subjects (48). The 12-month mortality rate for the
hole population was 3.2%. These revealing data illustrate
trikingly high vein graft failure rates, even with contempo-
ary practices.
Registry reports indicate that the prevalence of DM in
CI patients with prior CABG is rising. In the Mayo
linic, DM was recorded in 16% (1979 to 1989), 28%
1990 to 1994), and 30% (1995 to 1998) of PCIs performed
n patients with prior CABG (49). In the Washington
ospital Center, DM was recorded in 34% and 38% of
CIs performed in patients with prior CABG during 1990o 1994 and 1995 to 1998, respectively (50). In patients with cM who have recurrent ischemia despite medical therapy,
edo CABG has a much higher risk than PCI, and PCI
hould be the preferred option (51). Diabetes is associated
ith in-hospital mortality after SVG PCI, and DM predicts
LR and late cardiac events (5).
dverse Outcomes After PCI
rocedure-related and in-hospital outcomes. Although
ngiographic success after PCI occurs with a similar fre-
uency in diabetic and nondiabetic subjects (52,53), proce-
ural complications occur more frequently in DM (52,54).
his can largely be explained by the higher risk profile in
M (54).
In the American College of Cardiology-National Car-
iovascular Data Registry, the unadjusted in-hospital mor-
ality rate in 100,292 PCI cases (26% DM) performed in
39 centers during 1998 to 2000 was higher in diabetic
atients (1.8%) than in those without DM (1.3%; p 
.0001) (52). Fewer diabetic patients had no adverse events
n-hospital (96.2%) compared with nondiabetic patients
96.6%; p  0.009), and mean length of stay was greater in
iabetic patients (2.7 days) than in nondiabetic patients (2.4
ays; p  0.0001).
Renal dysfunction after PCI occurs more frequently in
M (55), and renal function should be checked in diabetic
atients after PCI (37). Surprisingly, DM does not predict
ardiac biomarker elevation after PCI (52,56).
Although diabetic patients undergo primary PCI less
ften and have a more adverse clinical profile than nondi-
betic subjects, in-hospital mortality is comparable in both
roups (57).
ong-term outcome after PCI. In the PRESTO (Preven-
ion of REStenosis with Tranilast trial and its Outcomes),
he largest contemporary restenosis trial to date, patients
ere stratified according to the presence (n  2,694) or
bsence of diabetes (n  8,798) (53). Compared with
ondiabetic patients, diabetic patients were older (mean age
1.8 vs. 59.8 years; p  0.01), more often had co-morbid
ealth problems, and had more complex culprit stenoses
e.g., higher prevalence of restenosis, calcified lesions, and
CC/AHA type C lesions). Even after adjustment for
ther differences in baseline characteristics, DM predicted
he 9-month rate of death (RR 1.87, 95% CI 1.31 to 2.68),
arget vessel revascularization (TVR) (RR 1.27, 95% CI
.14 to 1.42), and the composite of death/MI and TVR
RR 1.26, 95% CI 1.13 to 1.40).
In other studies, DM has predicted MACCE (56,58) and
ortality (23,54) in the longer term after PCI. The risk is
reatest in insulin-treated DM (23). Furthermore, DM
redicts mortality at 6 months after primary PCI (HR 1.53,
5% CI 1.03 to 2.26) (57).
Although PCI is generally preferable to repeat CABG,
CI for vein graft disease in DM might be particularly
roblematic (37). Insulin-treated DM is associated with
alcific vein graft degeneration (59).
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ncluded 2,229 consecutive patients (591 [27%] DM) who
ad undergone PCI with DES between April 2002 and
anuary 2004 (60). At 9-months’ follow-up, acute stent
hrombosis had occurred in 29 patients (1.3%) of whom 15
ad DM. Furthermore, DM was an independent predictor
f acute stent thrombosis (HR 3.71, 95% CI 1.74 to 7.89).
n-stent restenosis. Revascularization for restenosis is
ore common in diabetic patients than nondiabetic patients
fter PCI (53,54,61,62). In the PRESTO trial (53),
-month restenosis rates were 39.8% and 32.4% in diabetic
nd nondiabetic patients, respectively (p  0.01), and DM
ended to be a multivariate predictor of restenosis (OR 1.22,
5% CI .97 to 1.54).
In 1 retrospective analysis of 3,090 (n  418 [14%] with
M) clinical trial participants who had 6-month angio-
raphic follow-up, restenosis occurred in 550 of 2,672
20.6%) nondiabetic patients and 130 of 418 (31.1%)
iabetic patients (p  0.001) (62). Reduced body mass
Figure 2 Glycemic Control and Outcomes 1 Year After PCI
(A) Relationships between glycemic control and target vessel revascularization (TV
ships between TVR in diabetic patients treated with or without insulin and in patie
permission.ndex (BMI) (OR 0.92, 95% CI 0.85 to 0.99), larger
eference diameter before stenting (OR 0.38, 95% CI 0.20
o 0.70), and longer stented length of vessel (OR 1.03, 95%
I 1.00 to 1.06) were multivariate predictors of restenosis
62). Restenosis in DM is associated with excess intimal
brosis and reduced cell content (63).
isease progression. In the PRESTO trial (53), compared
ith nondiabetic patients, diabetic patients recorded a
igher frequency of new lesions at 9 months (30% vs. 26%;
 0.05). This difference was mainly due to the develop-
ent of more new lesions in the treated vessel of diabetic
atients (15% vs. 12%; p  0.04) rather than in non-treated
essels (20% vs. 18%; p  0.25).
etabolic control and outcomes after PCI. In a case-
ontrol investigation of glycemic status in 179 diabetic and
0 nondiabetic patients undergoing elective PCI (64),
bA1c 7% was a multivariate predictor of TVR at 12
onths after PCI (OR 2.87, 95% CI 1.13 to 7.24) (Fig. 2).
iabetic patients with suboptimal glycemic control (HbA1c
2 months after elective percutaneous coronary intervention (PCI). (B) Relation-
hout diabetes undergoing elective PCI. Reproduced from Corpus et al. (64) withR) at 1
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Diabetes and Coronary Heart Disease: Part II February 13, 2007:643–567%) were more often treated with insulin (54% vs. 27%),
nd insulin-treated patients had a higher rate of TVR,
ompared with non-insulin treated patients and control
ubjects (64) (Fig. 2). An HbA1c 7% was a multivariate
redictor of both cardiac repeat hospital stay (OR 2.44, 95%
I 1.05 to 5.66) and recurrent angina (OR 4.03, 95% CI
.66 to 9.78). One other angiographic follow-up study of
17 PCI patients (n 75 with DM) reported similar results
65).
In primary PCI, elevated admission blood glucose con-
entration (11 vs. 11 mmol/l) predicts early and long-
erm mortality (66).
MI and Outcome After
evascularization in Diabetic Patients
nfluence of BMI after PCI. Diabetes is common in obese
atients (BMI 30 kg/m2) undergoing revascularization
17% to 33%) (53,67–71), whereas low BMI is associated
ith advanced age, cigarette smoking, and peripheral vas-
ular disease (67). Perhaps surprisingly, obesity is not
ssociated with CHD severity (68,69).
There are conflicting reports about the influence of BMI
n long-term outcome after PCI. In the ARTS trial, 3-year
ACCE rates were similar in PCI patients who had a
ormal BMI (18.5 to 24.9 kg/m2; n  168 [28%]), who
ere overweight (BMI 25 to 30 kg/m2; n  307 [51%]), or
ho were obese (BMI 30 kg/m2; n  124 [20%]): 30.4%,
7%, and 32%, respectively (p  0.33) (70).
Reduced BMI is a predictor of restenosis in diabetic
atients (62). If low BMI is related to an increased risk of
ither restenosis or disease progression, then it might be
hat such patients have short stature and small caliber
oronary arteries (62,69), in which case low BMI might
egate the metabolic advantage of reduced body fat (67).
mall caliber arteries might be more common in diabetic
atients (62), and reference diameter is a predictor of
estenosis in diabetic patients after stenting (62).
nfluence of BMI after surgical revascularization. In the
RTS trial, the 3-year MACCE rates for surgical patients
ho had a normal BMI (n  169 [28%]), who were
verweight (n  299 [50%]), or who were obese (n  136
22%]) were 24%, 16%, and 11%, respectively (p  0.008)
70). In a multivariate analysis that included diabetes,
ncreasing BMI predicted a reduced rate of MACCE in
urgical patients (HR 0.59, 95% CI 0.39 to 0.89). This
bservation was mainly due to a lower rate of repeat
evascularization in obese patients.
By contrast, in the BARI trial, increasing BMI predicted
ll-cause mortality (adjusted p 0.04) and cardiac mortality
adjusted p  0.001) at 5 years (69). This finding might be
xplained by the adverse influence of cardiovascular risk
actors, more prevalent in obese patients, on long-term
utcomes after CABG (69). aecent Developments
n Diabetic Revascularization
n general, results of recent revascularization trials have been
pplied to diabetic patients on the basis of assumed efficacy
fter post hoc analyses and the absence of a negative
nteraction for diabetes status. We support current and
uture prospective revascularization trials (Table 3) exclu-
ively in diabetic patients.
dvances in management of surgical patients. Continu-
us insulin administration to achieve tight glycemic control
e.g., plasma glucose concentration 150 mg/dl, 8.3
mol/l) (72), improved use of secondary prevention thera-
ies (73), and use of arterial conduits rather than SVGs are
ssociated with improved outcomes after surgery.
dvances in PCI. Improved outcomes with contemporary
CI (24,37) are paralleled by increasing case complexity
24). Percutaneous coronary intervention is increasingly
elected as a revascularization option in DM. The propor-
ion of patients with DM treated by contemporary PCI has
ncreased (25.8%) compared with earlier PTCA registries
13.5%) (23).
ntithrombotic Drug
herapy and Revascularization
lopidogrel. In PCI-CURE (Clopidogrel in Unstable an-
ina to prevent Recurrent Events) trial (74), of the 504
38%) diabetic patients included, 32 (12.9%) of the
lopidogrel-treated patients and 42 (16.5%) of the placebo-
reated patients experienced cardiovascular death or MI
uring follow-up (HR 0.77, 95% CI 0.48 to 1.22). By
ontrast, in nondiabetic patients, a benefit in favor of
lopidogrel was apparent (HR 0.66, 95% CI 0.50 to 0.87).
Diabetic patients are more likely to be resistant to the
ffects of aspirin (75) or to have dual platelet resistance to
spirin and clopidogrel (75). The question of whether
nti-platelet resistance might contribute to adverse out-
omes after PCI in DM merits further investigation.
lycoprotein IIb/IIIa inhibitors. The results of recent
lycoprotein IIb/IIIa inhibitor trials in PCI are shown in
able 4 (76–79). A meta-analysis demonstrated a survival
dvantage conferred by abciximab in DM (4.5% vs. 2.5%;
 0.03) (80), and the 30-day mortality reduction associ-
ted with glycoprotein IIb/IIIa inhibitor in diabetic patients
ith non–ST-segment elevation acute coronary syndrome is
reater in patients undergoing PCI (81).
The NHLBI Dynamic Registry indicated planned glyco-
rotein IIb/IIIa inhibitor therapy in diabetes might reduce
he incidence of in-hospital death and death or non-fatal
I at 1 year after PCI (54). Abciximab might also be
eneficial in clopidogrel-treated diabetic patients undergo-
ng PCI (Table 4). The ISAR-SWEET trial prospectively
ested the effect of abciximab in diabetic PCI patients who
ad been pre-treated with 600 mg of clopidogrel (79).
lthough the combined primary end point rates of deathnd MI at 1 year were similar in abciximab and placebo-
Clinical Trials of Glycoprotein IIb/IIIa Inhibitor Therapy Involving Diabetic Patients
Table 4 Clinical Trials of Glycoprotein IIb/IIIa Inhibitor Therapy Involving Diabetic Patients
Trial (Ref.)
Randomization
Period Methods Primary End Point Patient Characteristics Primary End Point Results Primary End Point in DM Long-Term Follow-Up
ESPRIT (76) 1999–2000 Efficacy and safety of a
high-dose regimen
of eptifibatide as an
adjunct to elective
coronary stenting.
48-h composite of death,
non-fatal MI, urgent
TVR, and bailout with
glycoprotein IIb/IIIa
inhibitor therapy
Eptifibatide (n  1,040; 208 [20%] DM) or
placebo (n  1,024; 211 [21%] DM)
Eptifibatide: 6.6%
Placebo: 10.5%
RR 0.63 (95% CI 0.47–0.84)
p  0.0015
Eptifibatide: 3.9%
Placebo: 6.6%
RR 0.58 (95% CI
0.25–1.35)
p  0.20
1-yr follow-up, death
or MI 8.0%
eptifibatide group
and 12.4%
placebo group
(HR 0.63, 95% CI
0.48–0.83)
TARGET (77)
Impact in
diabetes (78)
1999–2000 Indication for non-
emergent PCI in a
native coronary
artery or bypass
graft; randomization
to tirofiban or
abciximab therapy
for 12–18 h or 12 h,
respectively;
patients stratified
according to
diabetic status at
enrolment
Composite of death, MI,
or urgent TVR at 30
days
4,089 enrolled
1,117 (23%) with diabetes (503 [45%]
insulin-treated): 560 tirofiban;
557 abciximab
Tirofiban group (7.6%); in
the abciximab group
(6.0%)
Superiority of abciximab
over tirofiban; p  0.038)
35 (6.2%) tirofiban and
30 (5.4%) abciximab
p  0.54
Among insulin-treated DM:
Tirofiban: 8.1%
Abciximab: 3.1%
p  0.02
DM TVR rate (10.3%)
at 6 months vs.
non-DM (7.8%;
p  0.008) and
trend to higher
1-yr mortality
(2.5% vs. 1.6%;
p  0.056)
ISAR-SWEET (79) January 2001
and October
2003
Elective PCI 600 mg of
clopidogrel and 500
mg of aspirin at
least 2 h before the
procedure BMS
Death or MI at 1 yr 701 DM patients (351 abciximab and 350
placebo)
29% insulin-treated, 51% on oral
hypoglycemic drugs only, and 20% on
no diabetic therapy at all (with equal
proportions in each group)
— 29 (8.3%) in abciximab and
30 (8.6%) in placebo),
*TLR 23.2% abciximab
and 30.4% placebo
(p  0.03)
—
*Follow-up angiography was performed at a median of 197 days (25th, 75th percentiles: 181, 220 days).
Abbreviations as in Tables 1 and 3.
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educed by abciximab (79) (Table 4). Adjunctive glyco-
rotein IIbIIIa inhibitor therapy represents an advance for
iabetic patients, particularly those undergoing complex
CI. Contemporary PCI guidelines recommend glyco-
rotein II/bIIIa inhibitors in patients with unstable CHD
nd in elective PCI patients with risk factors, such as
iabetes (37).
ivalirudin. The direct thrombin inhibitor, bivalirudin, is
n emerging alternative to the combination of heparin and
lycoprotein IIb/IIIa inhibitors during PCI. Further infor-
ation in diabetic patients undergoing PCI is required
efore this drug can be recommended (37).
mpact of antidiabetic therapies on outcome after PCI.
hiazolidinedione drugs, such as rosiglitazone, are PPAR-
amma inhibitors that have pleiotropic effects, including
mproved insulin sensitivity and enhanced endothelial cell
unction. Recent studies suggest thiazolidinedione drugs
ave anti-restenosis effects after PCI (82,83).
ngoing Interventional Trials in Diabetes
he BARI 2D trial is a 2  2 factorial trial, which will
esult in 50% of enrolled diabetic patients randomized to
edical therapy or revascularization, and within each of
hese 2 groups an additional randomization will take place
o insulin-providing or insulin-sensitizing agents (34) (Ta-
le 3). Other on-going trials include the CARDIA (Coro-
ary Artery Revascularization in DIAbetes) trial (35) and
he FREEDOM (Future REvascularization Evaluation in
atients with Diabetes mellitus: Optimal Management of
ultivessel disease) trial (36) (Table 3).
onclusions
n recent years, technical advances have resulted in greater
apability for revascularization with PCI coupled with
mproved safety.
Although randomized clinical trials provide information
ntended to guide clinical activity, data arising from these
rials are derived from highly selected populations that
ight not be fully representative of patients encountered in
rdinary clinical practice. Subgroup analyses should be
nterpreted with caution. Common limitations of some of
hese revascularization trials with respect to DM include a
ack of information about anti-diabetic therapy, glycemic
tatus, and duration and control of DM (e.g., glycemic
ontrol or the presence of DM complications). Conse-
uently, the effectiveness of PCI in diabetic patients with
table or unstable multivessel CHD (including the proximal
AD) is presently not supported by well established evi-
ence and has a Class IIb/C recommendation (37).
On the basis of this and on previous information, one can
each several conclusions that might serve as guidelines for
he contemporary invasive management of CHD patients
ith DM. In spite of a marked reduction of restenosis and
LR, with the use of BMS as compared with balloon
1ngioplasty in the late 1990s and early 2000s, the outcome
or diabetic patients was worse after PCI than after CABG
urgery. Diabetes mellitus is also a predictor of worse
utcome with CABG and might increase the risk for vein
raft occlusion and stenosis.
In the current era of DES, DM remains an independent
isk factor for restenosis and TLR. Conflicting results
etween clinical trials and their registries have created an
mperative for trials of revascularization strategies in DM.
he results of on-going randomized trials are awaited to
nform us on the comparative efficacy of contemporary PCI
nd CABG in patients with diabetes. Finally, better risk
actor control might decrease any difference between revas-
ularization strategies.
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